Urocortin-iii and uses thereof
CA 2425902 C · Owner: Perrin, Marilyn H. · Inventors: Vale, Wylie W. Jr.; Perrin, Marilyn H.; Lewis, Kathy A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A search of the public human genome database identified a human EST GenBank , accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2 the affinity for , CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2.alpha. or .beta.. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 2002 and granted January 3, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.